X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com//news-release/2023/11/06/2774415/0/en/Health-Canada-Approves-DOPTELET-avatrombopag-for-Two-Indications-in-Thrombocytopenia.html
https://www.prnewswire.com/news-releases/doptelet-avatrombopag-receives-positive-opinion-from-chmp-for-treatment-of-itp-301191178.html
https://seekingalpha.com/news/3621063-swedish-orphans-avatrombopag-flunks-late-stage-study-in-chemo-induced-low-blood-platelets
http://www.pharmatimes.com/news/nice_pushes_doptelet_for_pre-surgery_liver_disease_treatment_1328028
https://www.prnewswire.com/news-releases/dova-granted-orphan-drug-designation-for-avatrombopag-for-the-treatment-of-chemotherapy-induced-thrombocytopenia-300985361.html
https://www.prnewswire.com/news-releases/additional-analyses-from-phase-3-study-with-doptelet--avatrombopag-for-the-treatment-of-chronic-immune-thrombocytopenia-provides-evidence-of-long-term-response-rates-300971110.html
https://www.biopharmadive.com/news/sobi-acquires-dova-doptelet-rare-disease-hematology/564004/
https://www.fiercepharma.com/marketing/dova-takes-novartis-blockbuster-2nd-doptelet-fda-nod-slashes-price?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/marketing/cosmo-to-give-bausch-health-sales-a-run-latest-fda-nod-for-xifaxan-rival
https://endpts.com/dova-picked-up-its-newly-approved-drug-castoff-for-a-song-but-payers-will-be-singing-the-blues-about-the-price/
Market Place
Share 
